We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
GXP OXYCODONE, OXYCODONE JL, OXYCODONE NH, OXYCODONE NHPL, OXYCODOR LIQUID, OXYCODOR, OXYLENUS, OXYCODONE CP, OXYCODONE AB, OXYCODONE GPPL, OXYCODONE MLP, GXP OXYCODONE LIQUID, OXYNDONE, OXYLENUS LIQUID , OXYCODONE GENPAR, OXYCODONE GPPL LIQUID, OXYCODONE
Product name
GXP OXYCODONE, OXYCODONE JL, OXYCODONE NH, OXYCODONE NHPL, OXYCODOR LIQUID, OXYCODOR, OXYLENUS, OXYCODONE CP, OXYCODONE AB, OXYCODONE GPPL, OXYCODONE MLP, GXP OXYCODONE LIQUID, OXYNDONE, OXYLENUS LIQUID , OXYCODONE GENPAR, OXYCODONE GPPL LIQUID, OXYCODONE NEO HEALTH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
oxycodone hydrochloride
Registration type
New generic medicine
Indication
OXYCODONE GENPAR, OXYCODONE NEO HEALTH, OXYCODONE NHPL, OXYNDONE are indicated for the management of opioid-responsive, moderate to severe pain.
GXP OXYCODONE, GXP OXYCODONE LIQUID, OXYCODONE GPPL, OXYCODONE GPPL LIQUID, OXYLENUS, OXYLENUS LIQUID, OXYCODONE JL, OXYCODOR, OXYCODOR LIQUID, OXYCODONE NH, OXYCODONE MLP, OXYCODONE CP, OXYCODONE AB are indicated for the management of opioid-responsive moderate to severe pain.